MorphoSys AG (MOR) PT Set at €90.00 by Deutsche Bank AG
MorphoSys AG (ETR:MOR) has been assigned a €90.00 ($105.88) target price by stock analysts at Deutsche Bank AG in a research report issued to clients and investors on Monday. The firm presently has a “buy” rating on the stock.
Other equities research analysts have also issued research reports about the stock. J P Morgan Chase & Co set a €62.00 ($72.94) price objective on shares of MorphoSys AG and gave the stock a “neutral” rating in a report on Friday, August 4th. Berenberg Bank set a €68.00 ($80.00) price objective on shares of MorphoSys AG and gave the stock a “buy” rating in a report on Wednesday, August 16th. Independent Research GmbH set a €77.00 ($90.59) price objective on shares of MorphoSys AG and gave the stock a “buy” rating in a report on Thursday, September 7th. Goldman Sachs Group, Inc. (The) set a €55.00 ($64.71) price objective on shares of MorphoSys AG and gave the stock a “neutral” rating in a report on Monday, July 24th. Finally, Commerzbank Ag set a €76.00 ($89.41) price objective on shares of MorphoSys AG and gave the stock a “buy” rating in a report on Monday, July 24th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. MorphoSys AG has an average rating of “Buy” and an average price target of €79.00 ($92.94).
Shares of MorphoSys AG (ETR MOR) traded up 0.750% during mid-day trading on Monday, hitting €75.361. 1,018 shares of the stock were exchanged. MorphoSys AG has a 1-year low of €37.50 and a 1-year high of €80.67. The company’s 50-day moving average is €71.40 and its 200-day moving average is €62.93. The firm’s market cap is €2.19 billion.
COPYRIGHT VIOLATION NOTICE: “MorphoSys AG (MOR) PT Set at €90.00 by Deutsche Bank AG” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this report on another site, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/10/30/morphosys-ag-mor-pt-set-at-90-00-by-deutsche-bank-ag-2.html.
About MorphoSys AG
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Receive News & Ratings for MorphoSys AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys AG and related companies with MarketBeat.com's FREE daily email newsletter.